OncoMed Pharmaceuticals, Inc. (OMED)
(Delayed Data from NSDQ)
$0.89 USD
0.00 (0.00%)
Updated Apr 22, 2019 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[OMED]
Reports for Purchase
Showing records 1 - 19 ( 19 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
OncoMed and Mereo BioPharma Announce Proposed Merger; PT to $1.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
3Q18 Results; Platform Progress Heading Into SITC Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for OMED
Provider: ValuEngine, Inc
Industry: Medical - Biomedical and Genetics
OncoMed Reports Overall Clinical Benefit Rate of 85% in Interim Phase 1b Data in Ovarian Cancer at ESMO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
OncoMed Indicates Celgene Not Exercising Rosmantuzumab License Option
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
OncoMed Announces Publication of Single-Agent Navicixizumab Phase 1a Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
OncoMed Announces Celgene Not Exercising Option to License Navicixizumab; PT Lowered to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
Global Investment Conference: OncoMed Takeaways; Navicixizumab and Pipeline Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
2Q18 Results; Focus Remains on Navicixizumab in Ovarian Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
1Q18 Results: Pipeline Progressing According to Plan
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
Announces John Lewicki, PhD, as CEO; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
4Q17 Results: Active Search for CEO Continues; Reiterate Neutral Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
Waiting for Some Clarity Amidst the Chaos; Assuming Coverage With a Neutral and $3 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Industry: Medical - Biomedical and Genetics
Removing Demcizumab and Tarextumab From Estimates; Focus Shifts to IO and Earlier CELG Collab Programs; PT to $6 From $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Industry: Medical - Biomedical and Genetics
Demcizumab Misses in Pancreatic Cancer AND Bayer Leaves Wnt Programs; Lowering PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Industry: Medical - Biomedical and Genetics
4Q16: Fast Approaching Key Data and Opt-In Decisions
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Industry: Medical - Biomedical and Genetics
3Q16: Despite Development Shuffles, Focus Remains on 2017 Opt-in Decisions
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
Industry: Medical - Biomedical and Genetics
Initiating Coverage With a Buy Ahead of a Year of Possible Partner Opt-Ins
Provider: H.C. Wainwright & Co., Inc.
Analyst: DEEPAK S
|